I need to put details about my own story–and RVD “light,” on hold for a day to discuss some breaking news with you.

While we were busy being inspired–and reading nutritional tips to help us control our myeloma–there was a lot going on with the new myeloma therapies and the FDA.

Most of you probably know that I have been working on several new books about multiple myeloma. 

The Myeloma Beacon’s Virginia Li wrote an interesting report late last week, highlighting how “more is not necessarily better” when it comes to myeloma therapy.

Can’t a guy catch a break?

Interested in doing a bit of “light reading” this weekend?  Then don’t access the following three links I have been saving since November!

One year ago, a dear friend of mine passed-away after a long fight against multiple myeloma.  Ever notice how the myeloma usually wins?

I’m breathing a sigh of relief right now.

Yesterday I asked if this secondary cancer issue “is much to do about nothing, or something that concerns you enough to keep you up at night?”

The risk of developing a secondary cancer following years of ongoing treatment was a red-hot issue one year ago.

I haven’t written much about panobinostat , another new, combination drug lately.

I don’t post a lot of information about MGUS and smoldering multiple myeloma on this site.

Yesterday I set the stage for today’s report about research data which was featured at the International Myeloma Foundation’s Journalist Workshop Monday night.

I know, I know.  I’m falling behind!  I’m so busy collecting and analyzing newly released myeloma related research data, I have barely had time to write.

At the end of yesterday’s post, I wrote:

I just posted a press release from Celgene, announcing their 3rd quarter financials for 2011 on my MyelomaNews.com site.

The most common side-effects from taking the oral novel therapy agent, Revlimid, are allergic reactions.

Consecutive M-spike nonoclonal protein readings of 0.5–and now 0.6–seem to confirm my autologous stem cell transplant failed to vanquish my multiple myeloma.

Here is a LINK to a story the Myeloma Beacon ran late last week about a European study, featuring an existing cancer drug, bendamustine (trade name:  Treanda).

Yesterday I wrote about three anti-myeloma clinical studies involving carfilzomib, elotuzumab and panobinostat.